Can switching breast cancer drugs buy more time? new study aims to find out.
NCT ID NCT06928818
First seen May 02, 2026 · Last updated May 05, 2026 · Updated 1 time
Summary
This study is for people with advanced HER2-positive breast cancer whose current treatment (trastuzumab deruxtecan) has stopped working. Researchers want to see if switching immediately to another targeted drug (trastuzumab emtansine) can help control the cancer longer. About 100 participants in Korea will be followed to track how long the cancer stays under control and how well the new drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF BREAST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.